New Research on Multiple Myeloma

Last Updated: May 11, 2018

Dr. Julie Vose discusses new cancer research highlighted at ASCO’s 2016 Annual Meeting, covering a study about a new drug that could change standard treatment for multiple myeloma.


Cancer.Net®: Doctor-Approved Patient Information from ASCO®

Cancer Research News from the 2016 ASCO Annual Meeting

Plenary Studies Sunday, June 5, 2016

Julie M. Vose, MD, MBA, FASCO, ASCO PRESIDENT, 2015-2016

Julie M. Vose, MD, FASCO:  The abstract I'd like to talk about is for patients with relapsed multiple myeloma. And these patients were in a randomized phase three trial, they received standard of care therapy, which would be bortezomib and dexamethasone, with or without a monoclonal antibody daratumumab, which is an approved agent, fairly recently, for relapse patients with a single agent. This study-- this was the first interim analysis of this study, and what they found was that the patients that received the triple drug arm, with the daratumumab, had much higher complete response rate, overall response rate, and improved progression pre-survival at a short time period. This was a first analysis, and so they really found that even though it was a very short time, that it really improved their potential outcome. So I feel that this potentially could improve the therapy for patients with relapsed multiple myeloma. It may be able to increase the response rate so those patients can go on to high dose therapy and stem cell transplantation, and then in that way be able to improve their overall survival in the future.

[Closing and Credits]

Cancer.Net®: Doctor-Approved Patient Information from ASCO®

ASCO's patient education programs are supported by Conquer Cancer Foundation of the American Society of Clinical  

The opinions expressed in the video do not necessarily reflect the views of ASCO or the Conquer Cancer Foundation.

Requests for commercial use of this video should be submitted to

© 2017 American Society of Clinical Oncology®. All rights reserved

Sharing and personal publication of this video indicates your consent to the Terms of Use, viewable at: